AlphaGalileo is a service for the media.
Journalists should register for free access to embargoed
news and press office contact information.
Please register view details
Please register to view contact details
Please log in or register to view articles older than 3 months
This item is under embargo and is only visible to journalists
Bookmark this item in My Area
This item is bookmarked
Add comments to this news release
One of the strategies urgently required to combat the problem of increasing antimicrobial resistance is to develop novel antibiotics that are able to kill multidrug resistant bacteria. Under the EU Seventh Framework Programme (FP7) for Research and Development, 4.1 million Euro’s has been awarded to the “NABARSI” research project, which will undertake a cutting-edge drug discovery program of 36-month duration to identify and develop new antibiotics.
According to the UK’s Chief Medical Officer, Dame Sally Field, "Antimicrobial resistance poses a catastrophic threat. If we don't act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can't be treated by antibiotics.”
The research institutes cooperating in NABARSI will identify and evaluate inhibitors of specific enzymes involved in microbial protein synthesis (aminoacyl-tRNA synthetases) using a ‘multi-target’ approach that will kill resistant bacteria and will also help limit the emergence of antibiotic resistance to these newly developed compounds. Some success has already been booked using this approach via the marketed drug mupirocin, though this product possesses severe limitations.
The techniques to be used in the project include the development and use of novel computational and screening technologies, synthetic chemistry and advanced studies to understand the mechanism of action of these inhibitor compounds, all combined within a state-of-the-art drug discovery programme.
“With support from the European Union, the NABARSI project has the potential to develop urgently needed antibiotics to treat multidrug antibiotic resistant microorganisms” says Dr. John P. Hays, coordinator of NABARSI. “This pan-European approach is an excellent example of how a combination of academic and industrial research organizations, with support from the European Union, can cooperate to generate an integrated research network to benefit the health of all EU citizens.”
This item has been withdrawn. Registered users can contact the publishing organisation for further details by logging in